Clinical trial
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination…
NCT00337987 · Yale University, Other · Completed
Key facts
| NCT number | NCT00337987 |
|---|---|
| Title | A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma |
| Official title | A Pilot Phase II Study to Determine the Safety of the Combination of ONTAK (DAB389IL-2), an Interleukin-2 Fusion Toxin, in Combination With CHOP in Peripheral T-Cell Lymphoma |
| Lead sponsor | Yale University, Other |
| Collaborators | Eisai Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral T-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Ontak, CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy |
| Enrollment | 49 |
| Start date | Nov 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Jan 1, 2008 |
| First posted | Jun 20, 2006 |
| Last update posted | Feb 27, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: